The week in numbers Six days, July 12 to 17 of W29. The headline is Lilly's roughly $2.8B (up to $3.8B with CVRs) acquisition of AtaiBeckley for its psychedelic depression pipeline, announced July 16. The largest prints are completions, not originations: GSK / Nuvalent ($10.6B), Angelini

A drug-discovery company that out-licenses an asset to a larger partner ends up holding two very different things. One is a royalty on the partner's future sales, a contractual cash flow with a defined lifespan. The other is the rest of the pipeline, a set of

The Michael J. Fox Foundation for Parkinson's Research (MJFF) is the largest nonprofit funder of Parkinson's research in the world, and, unusually for this series, it files a full public tax return. It is donor-funded, evergreen, and structured as a grantmaker rather than an investor.

Vera Therapeutics spent six years turning a drug that had failed in lupus, MS, and arthritis into an approved kidney medicine. On 7 July 2026 the FDA cleared atacicept, and in the same moment flipped a dormant royalty owed to Merck KGaA into a live, cash-paying obligation. Vera is

A royalty monetisation is characterised separately by tax law, accounting, bankruptcy law, and its commercial terms. The four answers can differ on the same deal. Only the tax answer decides whether the upfront cash is income this year or deferred across the life of the stream. This piece covers how

The development funding bond is a royalty deal that was never a royalty: fixed multiple, fixed schedule, guaranteed by the parent, paid regardless of sales. Why both sides chose debt over a true sale, the tax and accounting logic, and why the structure stays a category of two.

A decade in, no token has paid a pharmaceutical royalty. When decentralized science finally produced a commercial deal, the money went to equity holders, which is exactly where securities law sends it. Every eighteen months someone announces that pharmaceutical royalties are about to go on-chain. The pitch is stable:

The week in numbers July 4 to July 11, 2026: four acquisitions, six royalty-bearing originations, one synthetic royalty (Oberland / MeiraGTx), one €3.0B structured-equity monetisation (Apollo / Bayer), one structured-credit refinancing (OrbiMed / TOI), one milestone cash event (Aligos), and two negative royalty re-rates (Ionis WAINUA, GSK / Alector)

Since the September 2025 analysis, the disease-linked bond category has separated into families that no longer behave alike. Instruments that place principal at risk on a parametric trigger or a measured outcome saw little or no new issuance in 2024 to 2026. Instruments that rest on a sovereign credit,